Spravato is covered by most commercial plans and by Medicare Part B when given in a certified office, with prior authorization. The drug lists at roughly $800 to $1,300 per session depending on dose, plus an administration fee for two hours of monitoring. The Janssen savings program can cut the drug cost to $10 per treatment for eligible commercial patients.
This page lays out the pricing structure, what each type of insurance does, how prior authorization works, and the situations where patients get surprised. At Stedfast Psychiatry we verify your benefits and give you an expected out-of-pocket figure before your first dose. No one starts induction without knowing what it costs.
Who it is for
This page is for anyone weighing Spravato who needs to understand the financial side: patients with employer or marketplace plans, Medicare beneficiaries, people on Medicare Advantage, people with Medicaid managed care, and self-pay patients. It also applies to family members helping an older relative navigate Part B. The rules differ meaningfully across these groups, and the biggest cost surprises come from assuming they are the same.
How it works
Spravato billing has two separate components. The first is the drug itself, billed by the number of 28 mg devices used: two for a 56 mg dose, three for 84 mg. The second is the administration and observation fee, which covers the supervised self-administration, blood pressure monitoring, the two-hour observation and the clinical assessment. Under Medicare and many commercial plans, these are billed together with specific HCPCS codes (G2082 for 56 mg and G2083 for 84 mg) that bundle the drug and the monitoring. Other commercial plans want the drug billed under its own code and the observation billed as an evaluation plus prolonged service.
Because the drug is physician-administered rather than dispensed at a pharmacy, it falls under the medical benefit of your plan, not the pharmacy benefit. That is why it is covered under Medicare Part B rather than Part D, and why your deductible and coinsurance for an office procedure apply rather than a prescription copay.
The wholesale acquisition cost of Spravato is approximately $900 to $1,300 per treatment session depending on whether a 56 mg or 84 mg dose is used, before insurance or manufacturer assistance.
Source: Janssen published pricing and Medicare average sales price files
Medicare covers Spravato under Part B using HCPCS codes G2082 (56 mg) and G2083 (84 mg), which bundle the drug and the required observation.
Source: Centers for Medicare and Medicaid Services, 2020 Physician Fee Schedule final rule
Under the SPRAVATO withMe savings program, eligible commercially insured patients may pay as little as $10 per treatment, subject to an annual maximum benefit; federal and state program beneficiaries are not eligible.
Source: Janssen CarePath program terms
Treatment-resistant depression carries roughly double the annual healthcare costs of non-resistant depression, driven by hospitalization and lost productivity.
Source: Amos et al., Journal of Clinical Psychiatry, 2018
What to expect
After your evaluation, our staff submit a prior authorization to your insurer with your diagnosis, the antidepressants you have tried and the dates, your rating scale scores and the treatment plan. Commercial approvals usually take three to ten business days. Medicare Part B does not require prior authorization, though your record must document medical necessity. Medicare Advantage plans usually do require it. Once approved, we give you an estimate for induction and for maintenance based on your deductible status and coinsurance. If the savings program applies, we enroll you before the first dose. If your plan denies coverage, we appeal; most denials we see are for missing documentation rather than a policy exclusion.
Benefits
- Covered by most commercial plans for treatment-resistant depression with prior authorization
- Covered by Medicare Part B as a physician-administered drug, with no prior authorization for original Medicare
- Janssen savings program can bring the drug cost to $10 per treatment for eligible commercial patients, up to an annual maximum
- Benefits verified and an expected out-of-pocket estimate provided before the first session
- Appeals handled by our staff when a plan denies an initial request
Risks and side effects
Financial risks worth naming: deductible timing, where starting induction in January means paying your full deductible before coinsurance kicks in; plan changes mid-treatment, since a new plan means a new authorization; Medicare Advantage plans that approve induction but require reauthorization for maintenance; and the savings program annual cap, which some high-frequency patients reach before year end. Self-pay patients should budget for the full course rather than a single session, because stopping after two or three sessions rarely produces a lasting benefit.
Cost and insurance
Rough figures to plan around, before insurance: the drug alone is roughly $800 to $900 for a 56 mg dose and $1,200 to $1,300 for 84 mg at list price, and the administration and observation fee adds several hundred dollars. A full first month of eight sessions therefore has a list cost in the low five figures. With commercial insurance after deductible, typical patient responsibility is a coinsurance percentage of the allowed amount, often reduced to the $10 drug copay under the savings program plus any cost share for the observation visit. With Medicare Part B, you owe 20 percent of the Medicare-allowed amount after the annual deductible, which a Medigap plan may cover in full. We will give you specific numbers for your plan at the evaluation.
Coverage by insurance type
| Coverage | Covers Spravato? | Prior authorization | Typical patient cost | Savings program |
|---|---|---|---|---|
| Commercial (employer or marketplace) | Most plans, for treatment-resistant depression and MDD with suicidal ideation | Yes, with documentation of two failed antidepressants | Deductible, then coinsurance on drug and visit; drug often $10 with savings card | Eligible |
| Original Medicare (Part B) | Yes, as a physician-administered drug | No, but medical necessity must be documented | Part B deductible, then 20 percent coinsurance; Medigap may cover | Not eligible |
| Medicare Advantage | Yes | Usually, through the plan | Plan-specific copay or coinsurance | Not eligible |
| Florida Medicaid managed care | Generally, with authorization | Yes | Little or no cost share if in network | Not eligible |
| TRICARE and VA | Varies; VA offers Spravato at many facilities | Yes | Program-specific | Not eligible |
| Self-pay | Not applicable | None | Full drug and administration cost; ask for our self-pay rate | Patient assistance program may provide free drug if income-eligible |
Understanding the two line items
When you receive an explanation of benefits for a Spravato session, you will typically see two or three lines. One is the drug, listed by the number of devices. One is the observation or administration service. Some plans add a short evaluation and management code for the pre-dose assessment. Under Medicare and many commercial plans, the G2082 and G2083 codes combine the drug and the observation into one line. The reason it matters: the savings card applies only to the drug line. If your plan applies coinsurance to the observation visit, you will have a cost share there even when the drug is $10.
Where patients get surprised
- Deductible resets. Starting induction in the first months of the year means the deductible is paid out of your early sessions. Starting late in the year can mean a reset in the middle of maintenance.
- Out-of-network observation. If your plan covers the drug but the office is out of network, the observation fee can be billed at out-of-network rates. Confirm that Stedfast Psychiatry is in network for your plan.
- Savings card caps. The annual maximum benefit is finite. Patients on weekly maintenance for the full year sometimes exhaust it.
- Reauthorization gaps. If a continuation authorization lapses, sessions in the gap can be denied. We submit renewals ahead of time, but ask if you are unsure whether yours is current.
- Dose increases. Moving from 56 mg to 84 mg adds a third device and raises the drug line. Under bundled codes the allowed amount changes accordingly.
Is it worth it?
Treatment-resistant depression is expensive on its own: more hospitalizations, more emergency visits, more lost workdays and more years of disability than depression that responds. Studies estimate the annual healthcare cost of treatment-resistant depression at roughly twice that of responsive depression. A treatment with a reasonable chance of remission after years of failure can be a sound investment even at full price, and with coverage it is often the least expensive effective option left. We will not tell you it is worth it for you; we will give you the numbers and the evidence and let you decide.
Spravato at Stedfast Psychiatry
We offer Spravato at three Palm Beach County offices, each with a dedicated monitoring room and staff trained under the Spravato REMS program:
- Boynton Beach: 10301 Hagen Ranch Rd, Suite D720, Boynton Beach, FL 33437
- Palm Beach Gardens: 11641 Kew Gardens Ave, Suite 209, Palm Beach Gardens, FL 33410
- Royal Palm Beach: 420 South State Road 7, Suite 112, Royal Palm Beach, FL 33414
Call the office nearest you or request an appointment online. The first step is an evaluation, in person or by telehealth, to confirm you are a candidate and to start insurance authorization.
Frequently asked questions
How much does Spravato cost without insurance?
The drug alone runs roughly $800 to $900 per 56 mg session and $1,200 to $1,300 per 84 mg session at list price, plus an administration and monitoring fee. A first month of eight sessions can therefore exceed $10,000 at list. Most patients do not pay list price. If you are uninsured, ask our office about self-pay pricing and about Janssen's patient assistance program, which provides free drug to some patients who meet income criteria.
Does Medicare cover Spravato?
Yes. Original Medicare Part B covers Spravato as a physician-administered drug given in a certified office, with no prior authorization required. You pay the Part B deductible and then 20 percent coinsurance of the allowed amount; a Medigap plan may cover that 20 percent. Medicare Advantage plans also cover it but usually require their own prior authorization and may use different cost sharing. We bill Medicare directly.
Does Medicaid cover Spravato?
Florida Medicaid and its managed care plans generally cover Spravato for treatment-resistant depression with prior authorization, but coverage rules and participating providers vary by plan. The Janssen savings program cannot be used with Medicaid by federal law. Call our office with your plan name and we will tell you whether we are in network and what the authorization requires.
Why is Spravato so expensive?
Three reasons. It is a patented brand-name drug with no generic, priced to recover development costs. It must be given in a certified setting with at least two hours of staff monitoring per dose, which is a real cost. And the dosing is frequent, with eight sessions in the first month alone. The price is a legitimate concern, which is why we confirm your coverage and any savings program eligibility before you begin.
What is the Janssen Spravato savings program?
SPRAVATO withMe is the manufacturer's support program. For patients with commercial insurance, the savings card can reduce the drug cost to as little as $10 per treatment, up to an annual maximum. It does not cover the administration fee, and it is not available to anyone with Medicare, Medicaid, TRICARE or other government insurance. The program also offers a patient assistance arm for uninsured patients who meet income criteria. Our staff enroll eligible patients before the first dose.
What does prior authorization for Spravato require?
Most plans ask for: a diagnosis of major depressive disorder documented with a rating scale such as the PHQ-9 or MADRS; names, doses and dates of at least two antidepressants that did not work in the current episode; confirmation that you are 18 or older; a treatment plan listing the dosing schedule; and confirmation that the office is REMS-certified. Some plans also require a trial of psychotherapy or of an augmentation medication. We assemble and submit all of this.
Will my insurance cover maintenance sessions?
Usually, but often with a reauthorization. Most commercial plans and Medicare Advantage plans authorize the initial eight-week course and then require documentation of response, usually a meaningful drop in your rating scale scores, to continue. Original Medicare does not require reauthorization. We track your scores at every session for exactly this reason, and we submit continuation requests before the current authorization lapses so that your schedule is not interrupted.
Is Spravato cheaper than ketamine infusions?
For most insured patients, yes, by a wide margin. IV ketamine for depression is off-label, so it is almost never covered, and clinics charge roughly $400 to $800 per infusion out of pocket, often $3,000 to $5,000 for an initial series. Spravato's list price is higher, but with commercial coverage and the savings program, or with Medicare, the patient's share is usually far lower than self-pay ketamine. Without any insurance, infusions can be cheaper per session.
Where this treatment is offered
- Boynton Beach, FL
10301 Hagen Ranch Rd, Suite D720 and Suite B710 - Palm Beach Gardens, FL
11641 Kew Gardens Ave, Suite 209 - Royal Palm Beach, FL
420 South State Road 7, Suite 112
Conditions this treats
If you are in crisis, call or text 988 or go to the nearest emergency room. Educational content; individual results vary. Reviewed by Dr. David Husted, board-certified psychiatrist.